1. Median overall survival was greater in the pembrolizumab group compared to the control group (12.7 months vs. 10.9 months). 2. Treatment-related adverse events were comparable among patients in either group. Evidence Rating Level: 1 (Excellent) Study Rundown: Biliary tract cancers are a complex group of epithelial tumors with a poor prognosis. The first-line therapy